Dyadic International (NASDAQ:DYAI) Issues Quarterly Earnings Results, Beats Expectations By $0.06 EPS

Dyadic International (NASDAQ:DYAIGet Free Report) issued its quarterly earnings data on Tuesday. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.06, Zacks reports. The business had revenue of $1.96 million for the quarter, compared to the consensus estimate of $1.05 million. Dyadic International had a negative net margin of 188.09% and a negative return on equity of 149.16%. During the same period in the previous year, the firm earned ($0.06) EPS.

Dyadic International Stock Up 1.8 %

Dyadic International stock opened at $1.14 on Friday. Dyadic International has a one year low of $0.93 and a one year high of $2.67. The business’s fifty day moving average is $1.13 and its 200 day moving average is $1.42. The company has a quick ratio of 5.39, a current ratio of 5.15 and a debt-to-equity ratio of 1.54.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and issued a $6.00 price target on shares of Dyadic International in a research note on Thursday.

View Our Latest Stock Report on DYAI

Dyadic International Company Profile

(Get Free Report)

Dyadic International, Inc, a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health.

Further Reading

Earnings History for Dyadic International (NASDAQ:DYAI)

Receive News & Ratings for Dyadic International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyadic International and related companies with MarketBeat.com's FREE daily email newsletter.